論文ID: CJ-20-1283
A 56-year-old male smoker with persistent chest pain was diagnosed with acute anterior ST-segment elevation myocardial infarction (STEMI). Coronary angiography revealed an extensive thrombus without impairment of coronary flow in the proximal left anterior descending artery (Figure A,B). Primary percutaneous coronary intervention (PCI) was withheld because in such setting it could lead to thrombus-related complications, such as distal embolization and acute stent occlusion, resulting in further deterioration of coronary flow. Subsequent coronary computed tomography angiography (CCTA) confirmed an atherosclerotic plaque with an extensive thrombus (Figure C–E). Fibrinolysis using monteplase (27,500 IU/kg), aimed at reducing the volume of the thrombus, and subsequent dual antiplatelet therapy were administered. Repeat CCTA 7 days later showed an obvious increase in luminal diameter and reduction in total thrombus volume at the culprit lesion (Figure F–I). Neither fusion thallium-201 stress cardiac scintigraphy nor CCTA showed any ischemia (Figure J).
(A,B) Coronary angiograms show haziness suggestive of a large thrombus. Comparison of coronary computed tomography angiography (CCTA) before (C–E) and after (F–H) fibrinolysis, and a cross-sectional image of the culprit lesion (I). (J) Fusion images of stress myocardial scintigraphy and CCTA visualize apex myocardial damage.
PCI for extensive residual thrombosis in spontaneous reperfused STEMI could lead to deterioration in coronary flow and remains controversial. Fibrinolytic therapy significantly reduces the thrombus burden and reportedly has the potential to reduce PCI-related complications or deferment of PCI.1 This is the first report of serial CCTA precisely evaluating residual thrombus after fibrinolysis, resulting in avoidance of PCI. Fibrinolytic therapy assisted by CCTA could provide a viable pharmacoinvasive strategy in reperfused STEMI patients with extensive thrombus.
None.
The patient provided informed consent to publish the case and any accompanying images.
Approved by the institutional review board. Reference no: 1-33.
The authors declare no conflicts of interest.